検索
Leap Therapeutics Inc
LPTXウォッチリストに追加
2.050USD
0.0000.00%
取引時間 （ET）15分遅れの株価
68.57M時価総額
損失額直近12ヶ月PER
詳細情報 Leap Therapeutics Inc 企業名
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Incの企業情報
企業コードLPTX
会社名Cypherpunk Technologies Inc
上場日Jan 24, 2017
最高経営責任者「CEO」Onsi (Douglas E)
従業員数52
証券種類Ordinary Share
決算期末Jan 24
本社所在地47 Thorndike Street
都市CAMBRIDGE
証券取引所NASDAQ Capital Market Consolidated
国United States of America
郵便番号02142
電話番号16172524343
ウェブサイトhttps://www.leaptx.com/
企業コードLPTX
上場日Jan 24, 2017
最高経営責任者「CEO」Onsi (Douglas E)
Leap Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
よくある質問
Leap Therapeutics Incの上位5名の株主は誰ですか？
Leap Therapeutics Incの上位5名の株主は以下のとおりです。Dr. James H. Cavanaugh, Ph.D.
Leap Therapeutics Inc（LPTX）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Leap Therapeutics Incの株式を保有している機関は114社あり、保有株式の総市場価値は約11.73Mで、全体の12.01%を占めています。2025Q4と比較して、機関の持ち株は-9047212.00増加しています。